All In Biotech

Drug Trial Radar · NCT05294731

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

146

Planned (sponsor's estimate)

Start

May 6, 2022

Primary completion

Jun 30, 2027

Study completion Jan 31, 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Mar 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

Conditions

  • B-cell Malignancy
  • Non-Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Waldenström Macroglobulinemia
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • DLBCL Unclassifiable
  • Richter's Transformation

Interventions

  • TacabrutidegDrug

    Orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From first dose of the study drug(s) to 30 days after the last dose or before initiation of a new anticancer therapy, whichever occurs first (up to approximately 3 years)
  2. Phase 1: Recommended Phase 2 dose (RP2D) of TacabrutidegTime frame: From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)
  3. Phase 1a: Maximum tolerated dose (MTD) of TacabrutidegTime frame: From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)
  4. Phase 2: Overall Response Rate (ORR) in participants with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)Time frame: Up to approximately 3 years
  5. Phase 2: ORR in participants with R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Time frame: Up to approximately 3 years

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chao Yang Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial Peoples Hospital Huifu Branch

    Guangzhou, Guangdong, China · Recruiting

  • The Peoples Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China · Recruiting

  • Nanyang Central Hospital

    Nanyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, China · Recruiting

  • Jiangxi Province Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Qingdao Central Hospital

    Qingdao, Shandong, China · Recruiting

  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Institute of Hematology and Hospital of Blood Disease

    Tianjin, Tianjin Municipality, China · Recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.